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PLEURAL COMPLICATIONS 
IN LUNG TRANSPLANT 
RECIPIENTS 
Pleural complications occurred in 30 (22%) of 138 patients after 53 single and 
91 double lung transplants between September 1986 and February 1993. These 
were defined for the purposes of this study as pneumothorax persisting beyond 
the first 14 postoperative days, recurrent pneumothorax, or any other pleural 
process that necessitated diagnostic or therapeutic intervention. Overall, a 
higher pleural complication rate was seen in double lung transplantation (25 
of 30) than in single lung transplantation (5 of 30) with no differences noted in 
the frequency among preoperative diagnostic groups (p > 0.05). Pneumotho- 
rax was the most frequent complication, affecting 14 of 30 patients, with 6 of 14 
cases occurring after transbronchial biopsy. All pneumothoraces in ingle (n = 
4) and double lung transplantation (  = 10) resolved spontaneously or with 
chest ube thoracostomy. One patient required placement of a Clagett window 
after open lung biopsy and another required thoracotomy and pleural abrasion 
after transbronchial biopsy. Parapneumonic effusion was observed in 4 of 30 
double lung transplantations with spontaneous resolution in all cases. Empy- 
ema affected 7 of 30 patients and occurred exclusively in the double lung 
transplant group. Sepsis developed in three of the patients with this compli- 
cation and they subsequently died. The risk of empyema was independent of
preoperative diagnosis (p > 0.05). Of interest, all patients with cystic fibrosis 
(n = 3) with complicating empyema had Pseudomonas cepacia in the pleural 
fluid. Other miscellaneous complications included subpleural hematoma, 
chylothorax, and hemothorax. The latter two necessitated thoracic duct and 
bronchial artery ligation, respectively. In summary, a significant proportion of 
lung transplant recipients will have pleural space complications. The vast 
majority of these will resolve spontaneously or with conservative procedures. 
These complications were not related to preoperative diagnosis nor associated 
with a significant prolongation ofhospital stay (p > 0.05). Empyema is the only 
pleural space complication associated with increased patient mortality and, as 
such, is an important clinical marker for those at risk for sepsis and death. 
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L ung transplantation is an accepted treatment in selected patients with end-stage lung disease. 14 
Although survival after lung transplantation was 
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initially hindered by technical limitations, continued 
evolution of organ preservation methods, surgical 
techniques, and postoperative management has sig- 
nificantly improved the likelihood of allograft sur- 
vival and function. 6-8 
As our experience with lung transplantation i - 
creases, we have become aware of other complica- 
tions that may lead to significant morbidity and 
mortality. One such area is that of pleural disorders. 
Pleural complications should not be surprising iven 
that (1) the pleural space is completely exposed, (2) 
patients are immediately given immunosuppressive 
agents, (3) patients may have had previous pleural 
procedures and complications (such as open lung 
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Table I. Indications for unilateral ung 
transplantation (n = 53*) 
Indication n 
Restrictive lung disease 25 
Idiopathic pulmonary fibrosis 19 
Scleroderma 2 
Sarcoidosis 1 
Extrinsic allergic alveolitis 1 
Postchemotherapy disease 1 
Asbestosis 1 
Obstructive lung disease 16 
al-Antitrypsin deficiency 5 
Eosinophilic granuloma 3 
Idiopathic emphysema 6 
Bronchiolitis 1 
Lymphangiomyomatosis 1 
Pulmonary hypertension 9 
Primary pulmonary hypertension 7 
Eisenmenger's syndrome 1 
Fibrosing mediastinitis 1 
*Retransplantation 3 
biopsies and pneumothoraces), (4) subgroups of 
patients have chronic sinopulmonary infection (that 
is, cystic fibrosis), and (5) frequent transbronchial 
biopsies are part of transplant surveillance proto- 
cols. 
We therefore sought to examine the nature and 
frequency of p!eural space complications in the 
Toronto Lung Transplant P rogram and their effect 
on patient outcome. Further knowledge of such 
complications may be useful in the future develop- 
ment of  protocols to lessen their frequency and 
minimize morbidity. 
Table II. Indications for bilateral ung 
transplantation (n = 91") 
Indication n 
Septic lung disease 35 
Cystic fibrosis 29 
Bronchiectasis 6 
Obstructive lung disease 41 
Emphysema 22 
a~-Antitrypsin deficiency 14 
Bronchiolitis obliterans 3 
Eosinophilic granuloma 2 
Pulmonary hypertension 7 
Eisenmenger's syndrome 3 
Primary pulmonary hypertension 4 
Restrictive lung disease 8 
Sarcoidosis 1 
pulmonary fibrosis 5 
Fibrosing alveolitis 2 
*Retransplantation 5 
Table I I I .  Preoperative diagnosis in patients with 
postoperative pleura{space complications 
SLT 5 
Pulmonary fibrosis 3 
al-Antitrypsin deficiency 1 
Emphysema 1 
DLT 25 
Cystic fibrosis 10 
Emphysema 7 
ai-Antitrypsin deficiencY 5 
Fibrosing alveolitis 1 
Primary pulmonary hypertension 1 
Eosinophilic granuloma 1 
Patients and methods 
Between November 1983 and February 1993 a total of 
53 single lung transplants (SLT) in 50 patients and 91 
double lung transplants (DLT) in 90 patients were done. 
Eight patients have undergone retransplantation (3 SLT, 
5 DLT). The indications for lung transplantation are listed 
in Tables I and II. Patient selection criteria have been 
described previously. 9 
Donor lung preservation. From 1983 to 1988, donor 
lungs were preserved by topical hypothermic mmersion 
only. After May 1988 donor lungs were flushed with 
crystalloid solution (either low-potassium dextran extra- 
cellular solution or modified Euro-Collins solution), and 
1 gm of prostaglandin E1 was infused intravenously orvia 
the main pulmonary artery immediately before pulmonary 
artery flush. 
Surgical technique 
SLT. Between November 1983 and May 1990, graft 
implantation was done in 39 patients according to a 
technique that included an omental wrap around the 
anastomosis. 6 Thereafter, the approach to bronchial anaS- 
tomosis was changed to the telescoping technique de- 
scribed by Calhoon and associates. 8 
DLT. Initial transplantation was done en bloc in 13 
patients with single venous and arterial anastomosis and a 
tracheal anastomosis; a second group of 5 patients under- 
went en bloc transplantation with single venous and 
arterial anastomosis, but bilateral bronchial anastomosis. 
Subsequently 22 patients underwent bilateral sequential 
SLT with separate vascular and bronchial end-to-end 
anastomoses. Since May 1990, all DLT procedures have 
been done with bilateral sequential single grafts with the 
telescoping bronchial technique. 
Immunosuppression. From 1983 to 1989, induction 
immunosuppression consisted of Minnesota antilympho- 
cyte globulin, cyclosporine, and azathioprine. Steroid ad- 
ministration was started 2 weeks after transplantation. 
Minnesota antilymphocyte globulin administration was 
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Table IV. Summary of pleural complications 
occurring in SLT and DLT 
Table V. Causes of pneumothorax in SLT and 
DL T recipients 
*Two patients had both empyema and pneumothorax. 
SLT 5 SLT 4 
Pneumothorax 4 Spontaneous 2 
Lymphoma 1 After transbronchial biopsy 2 
DLT 25* DLT 10 
Pneumothorax 10 Spontaneous 1 
Empyema 7 Postop. dehiscence 2 
Parapneumonic effusion 4 Postop. persistent air leak I 
Lymphoma 1 After transbronchial biopsy 4 
Hemothorax 2 After open lung biopsy 2 
Subpleural hematoma 1 
Chylothorax 1 
Pleural adhesion 1 stay for each diagnostic group was compared by analysis of 
variance. Data are expressed as mean plus or minus the 
standard error of the mean. 
started as a continuous infusion immediately after trans- 
plantation. The 10 to 20 mg/kg per day dosage was 
adjusted to achieve a desired lymphocyte count of 0.15 to 
0.30 • 103/ml, This was discontinued when adequate 
cyclosporine l vels were obtained, usually 5 to 7 days after 
transplantation. 
Cyclosporine was given perioperatively 1.5 to 3.0 mg/kg 
per day by continuous infusion with conversion to the oral 
preparation at5 to 10 mg/kg per day as Soon as tolerated. 
The dose was adjusted to obtain a whole blood trough 
level of 250 to 300 ng/ml in the first year and 170 to 250 
ng/ml thereafter. Azathioprine was given in a dosage of 
1.0 to 2.0 mg/kg per day. Since 1990, perioperative ste- 
roids have been given as follows: methylprednisolone 500 
mg intravenously before graft perfusion and for 4 days 
after transplant; then prednisone 0.5 mg/kg per day, 
tapering to 0.25 mg/kg during the first 6 to 9 months with 
a long-term aintenance dose after 1 year of 15 mg every 
other day. 
Surveillance and diagnosis of rejection. Acute rejec- 
tion is suspected when any of the following occur: dys- 
pnea, fatigue, fever, increased alveolar-arterial gradient, 
arterial oxygen desaturation on exercise, chest x-ray film 
abnormalities, or a decline in forced expiratory volume in 
1 second. Routine surveillance bronchoscopies have been 
instituted since 1988. Bronchoscopic examination with 
bronchoalveolar vage and transbronchial biopsy is done 
every 3 months during the first year, every 6 months 
during the second year, year b, thereafter, and whenever 
rejection is suspected. 1~ 
Study design. Charts from all cases of SLT and DLT 
were reviewed retrospectively and~the type and frequency 
of pleural space complications were recorded. Pleural 
complications for the purposes of this review were defined 
as pneumothorax persisting beyond the first 14 postoper- 
ative days and responsible for extending hospital stay; 
recurrent pneumothorax; or any other pleural process that 
necessitated iagnostic or therapeutic intervention, or 
both. The pleural complication rate was compared among 
different diagnostic groups and between SLT and DLT 
recipients by the Student's t and X z tests (Table III). 
Length of hospital stay after transplantation was evalu- 
ated as a means of assessing patient morbidity. Length of 
Results 
Demographics. SLT was done in 27 women and 
23 men. Three female patients underwent repeat SLT, 
which brought he total number of SLT procedures to 
53. Mean ages were 42.5 +_ 11.2 and 48.9 _+ 11.1 years, 
respectively. Of the 91 DLT procedures, 35 were done 
in women and 55 in men. Four women with SLT 
underwent DLT and 1 woman had DLT twice. Three 
women underwent SLT twice. Mean ages were 39.5 _+ 
11.9 and 40.9 _+ 13.4 years, respectively. 
Types of complications. Of the 138 patients in the 
transplant population, 30 (22%) were observed to 
have postoperative complications of the pleural 
space. Pneumothorax was the most frequent pleural 
complication observed and accounted for 14 of 30 
pleural space problems. There were seven cases of 
empyema nd four of parapneumonic effusion also 
observed in the transplant population. Other pleural 
space disorders occurred less frequently (Table IV). 
SLT versus DLT. Pleural complications occurred 
with a higher frequency in the DLT group than in 
the SLT group (27% versus 10%, p < 0.05). All 
pneumothoraces in SLT and 8 of 10 pneumothora- 
ces that occurred in DLT resolved spontaneously or 
with chest tube thoracostomy. There was no differ- 
ence in the frequency of pneumothoraces induced 
by transbronchial biopsies in SLT versus DLT (p > 
0.05). One patient required the placement of a 
Clagett window after open lung biopsy with a per- 
sistent bronchopleural fistula and another equired 
thoracotomy and pleural abrasion after transbron- 
chial biopsy. Several other causes of pneumothorax 
were seen only in DLT (Table V). 
Patients with septic lung disease and those with 
obstructive lung disease constituted the two largest 
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patient groups for which DLT was undertaken (n = 
76). There were no differences seen in the pleural 
complication rate between these two groups (29-% 
versus 33%,p > 0.05). Similarly, no differences were 
noted in the pleural complication rate in SLT when 
the two largest patient categories of restrictive lung 
disease and obstructive disease were compared 
(12% versus 18%, p > 0.05). 
Parapneumonic effusions occurred only in DLT 
and all resolved spontaneously. Empyema was ob- 
served only in DLT, with a frequency of 7 (8%) of 
91. There was no difference in the frequency of 
empyema in patients with obstructive lung disease 
versus the frequency in those with septic lung dis- 
ease (11% versus 8%, p > 0.05). One death related 
to sepsis occurred in each of the diagnostic groups 
with documented empyema: al-antitrypsin defi- 
ciency, emphysema, nd cystic fibrosis. All patients 
with cystic fibrosis with complicating empyema (n = 
3) had cultures positive for Pseudomonas cepacia. 
Patients with obstructive lung disease and compli- 
cating empyema had culture results showing methi'- 
cillin-resistant staphylococcus (n = 1), mixed gram- 
negative cultures (n = 2), and Pseudomonas 
aeruginosa (n = 1). Clagett windows were required 
in two of seven patients with empyema. Empyema 
was the only pleural complication associated with 
death. 
There was no significant difference in postopera- 
tive in-hospital length of stay between the SLT and 
DLT groups (Table VI). Similarly, no differences 
were observed when length of stay was compared 
among different preoperative diagnostic groups or 
between those patients with and without pleural 
complications. 
Discussion 
To date there has been only anecdotal disctission 
of pleural complications in the lung transplant liter- 
ature. This has occurred within the context of sev- 
eral descriptive case series that outlined the spec- 
trum of postoperative complications observed at 
individual transplant centers. 11' 12 Our experience 
shows that a significant proportion of the lung 
transplant population (30 of 138 or 22%) will have 
postoperative pleural space complications. The 
three most frequently observed complications were 
pneumothorax (14 of 30), empyema (7 of 30), and 
parapneumonic effusion (4 of 30). The nature of the 
procedure (SLT versus DLT) and the preoperative 
diagnosis did not influence the length of in-hospital 
stay or the type of pleural space complication. In our 
Table VI. Postoperative in-hospital length of stay 
for SLT and DLT with pleural space complications 
Days 
SLT 
Restrictive lung disease 51.67 -+ 7.87 
Obstructive lung disease 46.17 _+ 9.25 
Pulmonary hypertension 62.00 -+ 16.31 
DLT 
Septic lung disease 38.48 _+ 4.36 
Obstructive lung disease 36.15 -+ 3.47 
Pulmonary hypertension 32.80 +-- 6.78 
experience, the postoperative occurrence of either 
pneumothoraces or parapneumonic effusions was 
inconsequential. In the vast majority of cases these 
complications resolved spontaneously or with chest 
tube thoracostomy. They were never associated with 
increased patient mortality. 
Empyema was the only pleural space complica- 
tion ~tssociated with death. This was exclusively seen 
in the DLT population. This may reflect the in- 
creased infectious complication rate associated with 
the simultaneous violation of two pleural spaces in 
an immunocompromised host. Three of the seven 
patients in the empyema group died of sepsis- 
related complications. All patients with cystic fibro- 
sis with empyema (3 of 7) had cultures positive for 
Pseudomonas cepacia; however, there was only one 
death in that group. Patients in the ~l-antitrypsin 
deficiency group typically had mixed culture results. 
The only exception to this was one patient for whom 
the culture grew methicillin-resistant Staphylococcus 
aureus and who subsequently died with multiorgan 
system failure. The increased mortality associated 
with empyem a did not appear to be associated with 
the presence of preoperative septic lung disease. 
Raju and colleagues 11 noted a similarly bleak 
prognosis in a patient in their series in whom 
empyema developed. They described a 27-year-old 
woman with cystic fibrosis who underwent DLT. A 
postoperative mpyema developed, which subse- 
quently grew Pseudomonas aeruginosa. She died of 
septic complications on postoperative day 65. 
A low prevalence of pleural complications was 
recently described in patients undergoing thoracot- 
omy for lung carcinoma. 13 In this series of 103 
consecutive patients, there were three patients in 
whom pleural complications developed. There was 
one case of empyema, which was not fatal. One case 
each of bronchopleural fistula and pneumothorax 
with prolonged air leak was described, These results 
provide an interesting contrast to our data. As 
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previously discussed, we have hypothesized that 
simultaneous violation of two pleural spaces ignif- 
icantly increases the prevalence of observed pleural 
complications. In this lung carcinoma group under- 
going thoracotomy, all patients had only unilateral 
violation of the pleural space. Furthermore, these 
patients were not receiving immunosuppresive th r- 
apy and one would intuitively anticipate a much 
lower prevalence of septic complications. 
The vast majority of pleural complications in the 
postoperative lung transplant population appear 
inconsequential and are not associated with a signif- 
icant prolongation of hospital stay. Empyema was 
the only pleural space complication associated with 
increased patient mortality. The occurrence of em- 
pyema in our study was independent ofpreoperative 
lung disease and therefore it is difficult o speculate 
about possible patient risk factors or modes of early 
intervention to offset its development. A heightened 
clinical suspicion for the presence of empyema must 
be observed and an aggressive approach to the 
diagnosis and treatment should be undertaken to 
prevent septic complications and death. 
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